{
    "clinical_study": {
        "@rank": "55255", 
        "arm_group": [
            {
                "arm_group_label": "Evacetrapib (Fasted)", 
                "arm_group_type": "Experimental", 
                "description": "130 milligram (mg) oral dose of evacetrapib once daily in a fasted state for 10 days."
            }, 
            {
                "arm_group_label": "Evacetrapib (Fed)", 
                "arm_group_type": "Experimental", 
                "description": "130 milligram (mg) oral dose of evacetrapib once daily following a high-fat breakfast for 10 days."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to measure how much of the drug gets into the blood stream and\n      how long it takes the body to get rid of it when given to healthy participants. Information\n      about any side effects that may occur will also be collected.\n\n      The study has 2 periods. In each period, participants will take the study drug for 10 days,\n      either with or without a meal.  There is a minimum 14 day washout between each period.\n\n      This study is approximately 50 days, not including screening.  Screening is required within\n      28 days prior to the start of the study."
        }, 
        "brief_title": "Study of Food on Evacetrapib (LY2484595) in Healthy Participants", 
        "completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy participants as determined by medical history and physical examination\n\n          -  Have a body mass index of 18 to 32 kilograms per square meter (kg/m^2)\n\n          -  Are able to eat a high fat breakfast and abide by the food restrictions throughout\n             the study\n\n        Exclusion Criteria:\n\n          -  Have known allergies to evacetrapib, related compounds or any components of the\n             formulation\n\n          -  Have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of\n             the investigator, increases the risks associated with participating in the study\n\n          -  Regularly use known drugs of abuse and/or show positive findings on urinary drug\n             screening\n\n          -  Are participants who currently smoke cigarettes or use tobacco or nicotine\n             substitutes"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "86", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01810432", 
            "org_study_id": "14626", 
            "secondary_id": "I1V-MC-EIAX"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Evacetrapib (Fasted)", 
                    "Evacetrapib (Fed)"
                ], 
                "description": "Administered orally", 
                "intervention_name": "Evacetrapib", 
                "intervention_type": "Drug", 
                "other_name": "LY2484595"
            }, 
            {
                "arm_group_label": "Evacetrapib (Fed)", 
                "description": "Administered orally, at breakfast.", 
                "intervention_name": "High-fat Meal", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "August 23, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Daytona Beach", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "32117"
                }, 
                "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of Food on the Pharmacokinetics of Evacetrapib (LY2484595) in Healthy Subjects", 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Pharmacokinetics (PK): Maximum Concentration (Cmax) of Evacetrapib", 
                "safety_issue": "No", 
                "time_frame": "Predose up to 24 hours Post-dose Day 10 of Periods 1 and 2"
            }, 
            {
                "measure": "Pharmacokinetics (PK): Area under the Concentration Curve over a 24 Hour Dosing Interval (AUC\u03c4) of Evacetrapib", 
                "safety_issue": "No", 
                "time_frame": "Predose up to 24 hours Post-dose Day 10 of Period 1 and 2"
            }, 
            {
                "measure": "Pharmacokinetics (PK): Time of Maximum Observed Drug Concentration (tmax) of Evacetrapib", 
                "safety_issue": "No", 
                "time_frame": "Predose up to 24 hours Post-dose Day 10 of Period 1 and 2"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01810432"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}